Graves’ Disease Mechanisms: The Role of Stimulating, Blocking, and Cleavage Region TSH Receptor Antibodies

Abstract The immunologic processes involved in Graves’ disease (GD) have one unique characteristic – the autoantibodies to the TSH receptor (TSHR) – which have both linear and conformational epitopes. Three types of TSHR antibodies (stimulating, blocking, and cleavage) with different functional capabilities have been described in GD patients, which induce different signaling effects varying from thyroid cell proliferation to thyroid cell death. The establishment of animal models of GD by TSHR antibody transfer or by immunization with TSHR antigen has confirmed its pathogenic role and, therefore, GD is the result of a breakdown in TSHR tolerance. Here we review some of the characteristics of TSHR antibodies with a special emphasis on new developments in our understanding of what were previously called “neutral” antibodies and which we now characterize as autoantibodies to the “cleavage” region of the TSHR ectodomain.

[1]  M. Giménez-Barcons,et al.  Graves’ Disease TSHR-Stimulating Antibodies (TSAbs) Induce the Activation of Immature Thymocytes: A Clue to the Riddle of TSAbs Generation? , 2015, The Journal of Immunology.

[2]  I. Pujol-Autonell,et al.  How apoptotic β-cells direct immune response to tolerance or to autoimmune diabetes: a review , 2015, Apoptosis.

[3]  R. Latif,et al.  How one TSH receptor antibody induces thyrocyte proliferation while another induces apoptosis. , 2013, Journal of autoimmunity.

[4]  T. Gudermann,et al.  TSH induces metallothionein 1 in thyrocytes via Gq/11- and PKC-dependent signaling. , 2013, Journal of molecular endocrinology.

[5]  R. Latif,et al.  Antibody Protection Reveals Extended Epitopes on the Human TSH Receptor , 2012, PloS one.

[6]  J. Sanders,et al.  Thyrotrophin receptor antibody characteristics in a woman with long‐standing Hashimoto's who developed Graves' disease and pretibial myxoedema , 2012, Clinical endocrinology.

[7]  R. Latif,et al.  Delineating the autoimmune mechanisms in Graves’ disease , 2012, Immunologic research.

[8]  P. Pinton,et al.  Mitochondria-Ros Crosstalk in the Control of Cell Death and Aging , 2011, Journal of signal transduction.

[9]  G. Ning,et al.  Impairment of Regulatory Capacity of CD4+CD25+ Regulatory T Cells Mediated by Dendritic Cell Polarization and Hyperthyroidism in Graves’ Disease , 2011, The Journal of Immunology.

[10]  R. Núñez Miguel,et al.  Crystal structure of the TSH receptor (TSHR) bound to a blocking-type TSHR autoantibody. , 2011, Journal of molecular endocrinology.

[11]  T. Ando,et al.  Neutral antibodies to the TSH receptor are present in Graves' disease and regulate selective signaling cascades. , 2010, Endocrinology.

[12]  T. Tagami,et al.  ORIGINAL ARTICLE: Monoclonal autoantibodies to the TSH receptor, one with stimulating activity and one with blocking activity, obtained from the same blood sample , 2010, Clinical endocrinology.

[13]  S. Nagata,et al.  Autoimmunity and the Clearance of Dead Cells , 2010, Cell.

[14]  R. Paschke,et al.  The hinge region: an important receptor component for GPHR function , 2010, Trends in Endocrinology & Metabolism.

[15]  Hedda Wardemann,et al.  B-cell tolerance checkpoints in health and autoimmunity. , 2008, Current opinion in immunology.

[16]  B. Zheng,et al.  Local BAFF gene silencing suppresses Th17-cell generation and ameliorates autoimmune arthritis , 2008, Proceedings of the National Academy of Sciences.

[17]  M. Niedziela,et al.  Expression of Bcl-2 Family Proteins in Thyrocytes from Young Patients with Immune and Nonimmune Thyroid Diseases , 2008, Hormone Research in Paediatrics.

[18]  P. Santisteban,et al.  Gbetagamma dimers released in response to thyrotropin activate phosphoinositide 3-kinase and regulate gene expression in thyroid cells. , 2008, Molecular endocrinology.

[19]  B. Rapoport,et al.  The thyrotropin receptor hinge region is not simply a scaffold for the leucine-rich domain but contributes to ligand binding and signal transduction. , 2008, Molecular endocrinology.

[20]  A. Bossowski,et al.  Identification of apoptotic proteins in thyroid gland from patients with Graves' disease and Hashimoto's thyroiditis , 2008, Autoimmunity.

[21]  T. Ando,et al.  Antibody-induced modulation of TSH receptor post-translational processing. , 2007, The Journal of endocrinology.

[22]  Su He Wang,et al.  The role of apoptosis in thyroid autoimmunity. , 2007, Thyroid : official journal of the American Thyroid Association.

[23]  T. Blundell,et al.  Crystal structure of the TSH receptor in complex with a thyroid-stimulating autoantibody. , 2007, Thyroid : official journal of the American Thyroid Association.

[24]  J. Franklyn,et al.  Tag SNP screening of the PDCD1 gene for association with Graves’ disease , 2007, Clinical endocrinology.

[25]  S. Kalled,et al.  Treatment of autoimmune hyperthyroidism in a murine model of Graves' disease with tumor necrosis factor-family ligand inhibitors suggests a key role for B cell activating factor in disease pathology. , 2006, Endocrinology.

[26]  S. Avignone,et al.  Efficacy of rituximab treatment for thyroid-associated ophthalmopathy as a result of intraorbital B-cell depletion in one patient unresponsive to steroid immunosuppression. , 2006, European journal of endocrinology.

[27]  Rauf Latif,et al.  Thyrotropin receptor-associated diseases: from adenomata to Graves disease. , 2005, The Journal of clinical investigation.

[28]  R. N. Miguel,et al.  Characteristics of a monoclonal antibody to the thyrotropin receptor that acts as a powerful thyroid-stimulating autoantibody antagonist. , 2005, Thyroid : official journal of the American Thyroid Association.

[29]  T. Ando,et al.  Monoclonal Antibodies to the Thyrotropin Receptor , 2005, Clinical & developmental immunology.

[30]  K. Eguchi,et al.  Dissecting linear and conformational epitopes on the native thyrotropin receptor. , 2004, Endocrinology.

[31]  T. Blundell,et al.  Characteristics of a human monoclonal autoantibody to the thyrotropin receptor: sequence structure and function. , 2004, Thyroid : official journal of the American Thyroid Association.

[32]  J. Banga,et al.  Dynamics of thyroid-stimulating and -blocking antibodies to the thyrotropin receptor in a murine model of Graves' disease. , 2004, Endocrinology.

[33]  T. Ando,et al.  A monoclonal thyroid-stimulating antibody. , 2002, The Journal of clinical investigation.

[34]  B. Rapoport,et al.  Thyroid-stimulating autoantibodies in Graves disease preferentially recognize the free A subunit, not the thyrotropin holoreceptor. , 2002, The Journal of clinical investigation.

[35]  D. Aaronson,et al.  A Road Map for Those Who Don't Know JAK-STAT , 2002, Science.

[36]  G. Stassi,et al.  Autoimmune thyroid disease: new models of cell death in autoimmunity , 2002, Nature Reviews Immunology.

[37]  R. Ye Regulation of nuclear factor κB activation by G‐protein‐coupled receptors , 2001, Journal of leukocyte biology.

[38]  J. Klein,et al.  The Thyrotropin (Thyroid-Stimulating Hormone) Receptor Is Expressed on Murine Dendritic Cells and on a Subset of CD45RBhigh Lymph Node T Cells: Functional Role for Thyroid-Stimulating Hormone During Immune Activation1 , 2000, The Journal of Immunology.

[39]  S. Costagliola,et al.  Genetic immunization of outbred mice with thyrotropin receptor cDNA provides a model of Graves' disease. , 2000, The Journal of clinical investigation.

[40]  J. Mao,et al.  Guanine nucleotide exchange factor GEF115 specifically mediates activation of Rho and serum response factor by the G protein alpha subunit Galpha13. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[41]  C. Spitzweg,et al.  Journal of Clinical Endocrinology and Metabolism Printed in U.S.A. Copyright © 1998 by The Endocrine Society Thyrotropin Receptor Expression in Graves ’ Orbital Adipose/Connective Tissues: Potential Autoantigen in , 2022 .

[42]  A. Nagasaka,et al.  Changes in Free Radical Scavengers and Lipid Peroxide in Thyroid Glands of Various Thyroid Disorders , 1997, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[43]  K. Burman,et al.  Graves' IgG recognizes linear epitopes in the human thyrotropin receptor. , 1992, Biochemical and biophysical research communications.

[44]  E. Milgrom,et al.  Two-subunit structure of the human thyrotropin receptor. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[45]  N. Takasu,et al.  Graves' Disease Following Hypothyroidism Due To Hashimoto's Disease: Studies Of Eight Cases , 1990, Clinical endocrinology.

[46]  P. Buckland,et al.  Analysis of thyrotropin receptors by photoaffinity labelling. Orientation of receptor subunits in the cell membrane. , 1985, The Biochemical journal.

[47]  D. Doniach Autoimmunity , 1965, Current Opinion in Immunology.

[48]  R. Latif,et al.  Characterization of thyrotropin receptor antibody-induced signaling cascades. , 2009, Endocrinology.